RecruitingPhase 2NCT06311227
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Studying Classic hairy cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Robert J Kreitman, MPNational Cancer Institute LAO
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (21)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- City of Hope at Irvine Lennar, Irvine, California, United States
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Doral, Doral, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Hollywood, Hollywood, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- NCI - Center for Cancer Research, Bethesda, Maryland, United States
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06311227 on ClinicalTrials.govOther trials for Classic hairy cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06965114Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaNational Cancer Institute (NCI)
- RECRUITINGNANCT06781515Assessment of Disease Burden in Hairy Cell LeukemiaIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06774677Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06764524Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06561360A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06340737AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasStanford University
- RECRUITINGPHASE1NCT04815356Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and VariantNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT04322383Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantNational Cancer Institute (NCI)